Table 3. Results of multivariate Cox proportional hazards regression analysis for progression-free and overall survival.
| |
PFS |
||
|---|---|---|---|
| Variable | HR | 95% CI | P-value |
| CTC (⩾ vs <5) |
2.6 |
1.7−4.0 |
<0.001 |
| Bone-only metastatic disease |
0.5 |
0.3−0.8 |
0.015 |
|
Molecular subgroup | |||
| Luminal A | 1 | — | — |
| Luminal B–HER2-negative | 1.5 | 0.8−2.6 | 0.132 |
| Luminal B–HER2-positive | 0.7 | 0.4−1.1 | 0.113 |
| HER2-positive (non-luminal) | 0.7 | 0.3−1.5 | 0.364 |
| Triple negative |
1.8 |
1.0−3.4 |
0.071 |
|
OS |
|||
| |
HR |
95% CI |
P-value |
| CTC (⩾ vs 5) |
3.2 |
1.8−5.7 |
<0.001 |
| Age (⩾ vs < median) |
2.5 |
1.4−4.6 |
0.003 |
| Time-to-metastasis (⩾ vs 5 years from diagnosis) |
0.5 |
0.2−1.0 |
0.026 |
| Visceral metastatic disease |
1.7 |
1.0−3.1 |
0.056 |
|
Molecular subgroup | |||
| Luminal A | 1 | — | — |
| Luminal B–HER2-negative | 1.8 | 0.8−4.0 | 0.146 |
| Luminal B–HER2-positive | 0.8 | 0.4−1.7 | 0.592 |
| HER2-positive (non-luminal) | 0.1 | 0.02−1.1 | 0.057 |
| Triple negative | 2.0 | 0.9−4.3 | 0.097 |
Abbreviations: CI=confidence interval; CTC=circulating tumour cells; OS=overall survival. Bold values indicate significant P-values (P<0.05).